Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant.

Clinical course and therapeutic trial for a case of congenital secretory diarrhea due to novel GUCY2C variant.

Journal: American journal of medical genetics. Part A
Published: June 20, 2023

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.

Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.

Journal: Clinical breast cancer
Published: May 18, 2023

Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.

Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.

Journal: PloS one
Published: March 15, 2023

Therapy Development for Microvillus Inclusion Disease using Patient-derived Enteroids.

Therapy Development for Microvillus Inclusion Disease using Patient-derived Enteroids.

Journal: bioRxiv : the preprint server for biology
Published: February 07, 2023

Patient-derived enteroids provide a platform for the development of therapeutic approaches in microvillus inclusion disease.

Patient-derived enteroids provide a platform for the development of therapeutic approaches in microvillus inclusion disease.

Journal: The Journal of clinical investigation
Published: January 31, 2023

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

Journal: Breast cancer research and treatment
Published: May 09, 2022

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).

Journal: Alimentary pharmacology & therapeutics
Published: July 20, 2021

Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case Report.

Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case Report.

Journal: Oncology and therapy
Published: January 15, 2021

Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review.

Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review.

Journal: International journal of general medicine
Published: December 03, 2020

Analysis of Lung Gene Expression Reveals a Role for Cl- Channels in Diisocyanate-induced Airway Eosinophilia in a Mouse Model of Asthma Pathology.

Analysis of Lung Gene Expression Reveals a Role for Cl- Channels in Diisocyanate-induced Airway Eosinophilia in a Mouse Model of Asthma Pathology.

Journal: American journal of respiratory cell and molecular biology
Published: February 27, 2020

Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.

Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.

Journal: Journal of natural products
Published: January 25, 2020

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.

Journal: Clinical and translational gastroenterology
Published: December 05, 2019
Showing 1-12 of 40

Last Updated: 10/31/2025